Australian survey reports limited interest in CAB-LA PrEP by gay and bisexual men

22 November 2025. Related: Journal scan, Treatment access, HIV prevention and transmission.

Simon Collins, HIV i-Base

A recent cross-sectional Australian survey of gay and bisexual men reported a limited preference for CAB-LA.

Out of over 1680 responses the most preferred options were monthly oral pills (28%), followed by six-monthly injections (24%), removable implants (15%), daily oral (14%), event-driven oral (13%), and CAB-LA (4%).

This perhaps supports the decision by NICE in the UK to only fund limited access to CAB-LA for approximately 1000 people each year who are unable to take oral PrEP. [2]

Reference

1. Chan C et al. Assessing Demand for Long-Acting Injectable PrEP and Emerging PrEP Options for HIV Prevention in Australia: Results from a Cross-Sectional Survey of Men Who have Sex with Men. AIDS Behav (2025).
   https://doi.org/10.1007/s10461-025-04969-4
2. HTB. NICE approves limited access to injectable cabotegravir PrEP in England and Wales + BHIVA notes on prescribing. (17 October 2025).
   https://i-base.info/htb/52527